Deep Brain Stimulation (DBS) – Treatment of Parkinson’s Disease Parkinson’s disease is a movement disorder commonly seen in middle-aged and elderly people. It is characterized by resting tremor, muscle rigidity and slow movements. Deep brain electrical stimulation (DBS) is a neuromodulation therapy that is considered the most significant breakthrough in the treatment of Parkinson’s disease in the past 30-40 years. It is different from previous surgical procedures, and through the implantation of deep brain electrodes, it stimulates the relevant nuclei in the brain that control movement, eliminates the symptoms of Parkinson’s disease and restores the patient’s ability to move and care for themselves, which can greatly improve the patient’s quality of life and daily living ability, and is minimally invasive, reversible It has the outstanding advantages of being minimally invasive, reversible, adjustable, developable and bilateral, etc. Currently, more than 100,000 patients worldwide have received DBS treatment. ”The Deep Brain Stimulation System, commonly known as a “brain pacemaker”, is similar in appearance and principle of operation to a cardiac pacemaker. It consists of a stimulation electrode implanted in the brain, a pulse generator buried under the chest and a subcutaneous wire. The patient can feel the improvement of symptoms by turning on the electrode switch during the operation and can cooperate with the surgeon for the initial adjustment. After the operation, different stimulation parameters are selected according to the condition and adjusted by in vitro program control to achieve the best stimulation effect. The latest research shows that DBS can effectively control symptoms, but also has a certain neuroprotective effect, which can slow down the progression of the disease. So, which patients are suitable for DBS therapy? Indications for DBS therapy: Primary Parkinson’s disease; good results on levodopa; drug efficacy has significantly decreased or severe motor fluctuations or isokinetic disorders that affect quality of life; except dementia and severe psychiatric disease. Patient age: generally no older than 75 years; relaxable to about 80 years after individualized assessment of benefit and risk; patients with predominantly severe tremor may have an appropriate relaxation of the age limit.